<DOC>
	<DOCNO>NCT00037817</DOCNO>
	<brief_summary>Background : Previously demonstrate induction tumor antigen tumor suppressor gene expression lung cancer cell follow exposure DNA demethylating agent , Decitabine ( DAC ) . We also demonstrate DAC mediate target gene expression apoptosis significantly enhance cancer cell subsequent exposure histone deacetylase ( HDAC ) inhibitor Depsipeptide FK228 ( DP ) . Furthermore , demonstrate follow DAC , DAC/DP exposure , cancer cell recognize cytolytic T cell specific cancer testis antigen , NY-FSO-1 . This Phase I study evaluate gene induction thoracic oncology patient mediate sequential DAC/DP treatment without selective COX-2 inhibitor , celecoxib . Objectives : Evaluation pharmacokinetics toxicity continuous 72-hour intravenous Decitabine ( DAC ) infusion follow 4-hour intravenous infusion Depsipeptide FK228 ( DP ) without oral celecoxib patient unresectable cancer involve lung pleura . Analysis NY-ESO-1 , p16 p21 expression cancer specimens sequential Decitabine/Depsipeptide treatment . Analysis serologic response NY-ESO-1 sequential drug treatment . Analysis apoptosis tumor biopsy sequential Decitabine/Depsipeptide treatment . Refinement laser capture microdissection micro-array technique analysis gene expression profile tumor tissue . Eligibility : Patients histologically cytologically proven primary small cell non-small cell lung cancer , advance esophageal cancer , pleural mesothelioma , non-thoracic cancer metastasis lung pleura . Patients must 18 year old ECOG performance status 0-2 adequate pulmonary reserve evidence FEV1 DLCO great 30 % predict , less 50 mm Hg p02 great 60 mm Hg room air ABG . Patients must platelet count great 100.000. ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin le 1.5 x upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . Design : Patients inoperable malignancy involve lung pleura receive two cycle 72-hour intravenous infusion Decitabine follow 4-hour Depsipeptide infusion use Phase I study design . Decitabine administer continuous infusion day 1-4 , patient cohort receive escalate dos Depsipeptide administer day 4 day 10 34 day cycle . Once MTD toxicity sequential DAC/DP identify , additional cohort 6 lung cancer patient 6 mesothelioma patient receive sequential DAC/DP administer MTD outline celecoxib ( 400mg bid ) administer day 4-34 treatment cycle , mean enhance target cell apoptosis facilitate anti-tumor immune recognition/response . Pharmacokinetics , systemic toxicity , response therapy record . Tumor biopsy obtain prior , therapy evaluate expression NY-ESO-1 tumor antigen , well p16 p21 tumor suppressor gene , know modulate chromatin structure . Additional analysis undertaken evaluate extent apoptosis tumor tissue , determine immune recognition NY-ESO-1 demonstrate follow sequential DAC ? DP +/- celecoxib treatment . As exact set comparison analysis perform determine follow completion trial base limited number patient , analysis consider exploratory hypothesis generate rather definitive . A total 40 patient enrol .</brief_summary>
	<brief_title>Phase I Study Gene Induction Mediated Sequential Decitabine/Depsipeptide Infusion With Without Concurrent Celecoxib Subjects With Pulmonary Pleural Malignancies</brief_title>
	<detailed_description>Background : Previously demonstrate induction tumor antigen tumor suppressor gene expression lung cancer cell follow exposure DNA demethylating agent , Decitabine ( DAC ) . We also demonstrate DAC mediate target gene expression apoptosis significantly enhance cancer cell subsequent exposure histone deacetylase ( HDAC ) inhibitor Depsipeptide FK228 ( DP ) . Furthermore , demonstrate follow DAC , DAC/DP exposure , cancer cell recognize cytolytic T cell specific cancer testis antigen , NY-FSO-1 . This Phase I study evaluate gene induction thoracic oncology patient mediate sequential DAC/DP treatment without selective COX-2 inhibitor , celecoxib . Objectives : Evaluation pharmacokinetics toxicity continuous 72-hour intravenous Decitabine ( DAC ) infusion follow 4-hour intravenous infusion Depsipeptide FK228 ( DP ) without oral celecoxib patient unresectable cancer involve lung pleura . Analysis NY-ESO-1 , p16 p21 expression cancer specimens sequential Decitabine/Depsipeptide treatment . Analysis serologic response NY-ESO-1 sequential drug treatment . Analysis apoptosis tumor biopsy sequential Decitabine/Depsipeptide treatment . Refinement laser capture microdissection micro-array technique analysis gene expression profile tumor tissue . Eligibility : Patients histologically cytologically proven primary small cell non-small cell lung cancer , advance esophageal cancer , pleural mesothelioma , non-thoracic cancer metastasis lung pleura . Patients must 18 year old ECOG performance status 0-2 adequate pulmonary reserve evidence FEV1 DLCO great 30 % predict , less 50 mm Hg p02 great 60 mm Hg room air ABG . Patients must platelet count great 100.000. ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin le 1.5 x upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . Design : Patients inoperable malignancy involve lung pleura receive two cycle 72-hour intravenous infusion Decitabine follow 4-hour Depsipeptide infusion use Phase I study design . Decitabine administer continuous infusion day 1-4 , patient cohort receive escalate dos Depsipeptide administer day 4 day 10 34 day cycle . Once MTD toxicity sequential DAC/DP identify , additional cohort 6 lung cancer patient 6 mesothelioma patient receive sequential DAC/DP administer MTD outline celecoxib ( 400mg bid ) administer day 4-34 treatment cycle , mean enhance target cell apoptosis facilitate anti-tumor immune recognition/response . Pharmacokinetics , systemic toxicity , response therapy record . Tumor biopsy obtain prior , therapy evaluate expression NY-ESO-1 tumor antigen , well p16 p21 tumor suppressor gene , know modulate chromatin structure . Additional analysis undertaken evaluate extent apoptosis tumor tissue , determine immune recognition NY-ESO-1 demonstrate follow sequential DAC ? DP +/- celecoxib treatment . As exact set comparison analysis perform determine follow completion trial base limited number patient , analysis consider exploratory hypothesis generate rather definitive . A total 40 patient enrol .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients histologically cytologically proven primary small cell nonsmall cell lung cancer , advanced esophageal cancer , pleural mesothelioma eligible evaluation . In addition , patient cancer nonthoracic origin metastasis lung pleura eligible evaluation . Patients intracranial metastasis treat surgery radiation therapy may eligible study provide evidence active disease requirement anticonvulsant therapy steroid follow treatment . Patients prior Decitabine Depsipeptide exposure eligible study provide experienced dose limit toxicity dose DAC DP schedule receive . Patients prior current celecoxib exposure eligible study provide intermittent , short term duration ( less 1 month ) . Patients must chemotherapy , biologic therapy , celecoxib exposure , radiation therapy malignancy within 30 day prior treatment . Patients may receive localized radiation therapy nontarget lesion provide radiotherapy complete 14 day prior commence therapy , patient recover toxicity . Patients must ECOG performance status 02 . Patients must adequate pulmonary reserve evidence FEV1 DLCO great 30 % predict , pCO2 less 50 mm Hg pO2 great 60 mm Hg room air ABG . Patients must 18 year age old due unknown effect demethylating agent HDAC inhibitor childhood adolescent development . Patients must platelet count great 100 , 000 , ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin le 1.5 x upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . All patient cardiology consultation . Subsequent evaluation consist stress/redistribution thallium , 24th ambulatory EKG monitoring , ECHO , cardiac MR , coronary angiography indicate . Patients must aware neoplastic nature his/her illness , experimental nature therapy , alternative treatment , potential benefit , risk . The patient must willing sign inform consent , undergo tumor biopsy evaluate target gene expression prior , , decitabine/depsipeptide treatment . EXCLUSION CRITERIA : Patients primary metastatic cancer involve lung pleura readily biopsied endoscopic percutaneous fine needle aspiration technique exclude . Patients untreated limited stage SCLC , operable NSCLC operable esophageal cancer exclude . Patients receive three systemic cytotoxic treatment regimens exclude due possible cumulative marrow suppression . Patients active intracranial leptomeningeal metastasis well require anticonvulsant medication exclude . Patients life expectancy less three month exclude . Patients pulmonary embolism , deep venous thrombosis , prosthetic heart valve require anticoagulation exclude . Cardiac exclusion criterion , patient know cardiac abnormality : Uncontrolled arrhythmias History serious ventricular arrhythmia control coronary artery bypass surgery . Patients history sustain VT , VF , Toursades de Pointes , cardiac arrest automatic implantable cardioverter defibrillator place Congenital Long QT syndrome QTc great 480 msec Patients Mobitz II second degree block pacemaker Patients cardiac arrhythmia require antiarrhythmic medication beta blocker calcium channel blocker Patients digitalis discontinue Decompensated heart failure ( NYHA Class II IV ) LVEF le 50 % MUGA scan echocardiogram Hypertrophic restrictive cardiomyopathy prior treatment cause patient leave ventricular hypertrophy Uncontrolled hypertension ( i.e great equal 160/95 ) Myocardial infarction within one year study Clinical significant active myocardial ischemia basis nuclear image angiography History coronary artery disease ( e.g . angina Canadian Class IIIv positive stress image study ) Patients cardiac disease may exclude discretion PI follow consultation cardiology Comedication cause QTc prolongation unless 5 halflife washout period elapse discontinue drug enter study . Pregnant patient lactate mother exclude due unknown , potentially harmful effect demethylating agent HDAC inhibitor fetal early childhood development . Patients active infection exclude . Patients HIV infection exclude due potential risk opportunistic infection DAC/DPinduced myelosuppression potentially deleterious activation viral gene expression . Patients use hydrochlorothiazide diuretic enter protocol . Therefore , patient must use hydrochlorothiazide diuretic exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 30, 2016</verification_date>
	<keyword>Toxicity Evaluation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Gene Induction</keyword>
	<keyword>Gene Expression</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Pleural Mesothelioma</keyword>
</DOC>